Table 3.
Univariate analysis of lymph node harvested
| Variable | N(%) | Total lymph nodes harvested, M (IQR) | P value |
|---|---|---|---|
| Group | 0.000** | ||
| Non-injection | 66(60.6%) | 14.0(5) | |
| Pre-neoadjuvant Injection | 22(20.2%) | 20.0(7) | |
| Preoperative injection | 21(19.3%) | 16.0(5) | |
| Gender | 0.637# | ||
| Female | 38(34.9%) | 15.5(6) | |
| Male | 71(65.1%) | 15.0(6) | |
| Age | 0.656# | ||
| ≤ 50 | 28(25.7%) | 16.0(7) | |
| > 50 | 81(74.3%) | 15.0(7) | |
| BMI | 0.875** | ||
| < 18.5 kg/m2 | 2(1.8%) | 18.0(-) | |
| 18.5–24.9 kg/m2 | 81(74.3%) | 15.0(7) | |
| 25.0–29.9 kg/m2 | 23(21.1%) | 15.0(4) | |
| ≥ 30 kg/m2 | 3(2.8%) | 18.0(-) | |
| Comorbidity | 0.751# | ||
| No | 68(62.4%) | 15.0(6) | |
| Yes | 41(37.6%) | 16.0(7) | |
| Pre-treatment cT stage | 0.687** | ||
| T2 | 3(2.8%) | 14.0(-) | |
| T3 | 77(70.6%) | 15.0(6) | |
| T4 | 29(26.6%) | 15.0(7) | |
| Pre-treatment cN stage | 0.243** | ||
| N0 | 5(4.6%) | 16.0(9) | |
| N1 | 36(33.0%) | 14.0(7) | |
| N2 | 68(62.4%) | 15.5(6) | |
| Tumor distance from anal verge | 0.342# | ||
| ≤ 5 cm | 74(67.9%) | 15.0(5) | |
| > 5 cm | 35(32.1%) | 18.0(8) | |
| Surgical approach | 0.744# | ||
| Laparoscopy | 104(95.4%) | 15.0(6) | |
| Laparotomy | 5(4.6%) | 14.0(17) | |
| Surgical procedure | 0.455** | ||
| Dixon | 8(7.3%) | 15.0(7) | |
| Dixon + colostomy | 74(67.9%) | 15.5(7) | |
| Harrtmann | 1(0.9%) | - | |
| Miles | 26(23.9%) | 15.0(5) | |
| inferior mesenteric artery ligation level | 0.195# | ||
| high | 54(49.5%) | 15.0(5) | |
| low | 55(50.5%) | 18.0(7) | |
| ASA classification | 0.656# | ||
| II | 94(86.2%) | 15.0(7) | |
| III | 15(13.8%) | 14.0(5) | |
| pT stage | 0.451** | ||
| T0 | 12(11.0%) | 15.5(9) | |
| T1 | 5(4.6%) | 14.0(5) | |
| T2 | 21(19.3%) | 15.0(8) | |
| T3 | 68(62.4%) | 15.0(6) | |
| T4 | 3(2.8%) | 19.0(-) | |
| pN stage | 0.826** | ||
| N0 | 73(67.0%) | 15.0(7) | |
| N1 | 28(25.7%) | 15.0(6) | |
| N2 | 8(7.3%) | 15.0(6) | |
| yp TNM stage | 0.514** | ||
| 0 | 11(10.1%) | 14.0(9) | |
| I | 22(20.2%) | 14.5(6) | |
| II | 40(36.7%) | 16.0(7) | |
| III | 36(33.0%) | 15.0(6) | |
| Differentiation | 0.266** | ||
| Low | 18(16.5%) | 14.0(2) | |
| Middle | 66(60.6%) | 16.0(6) | |
| Unknown | 25(22.9%) | 17.0(8) | |
| Tumor regression grade | 0.863** | ||
| 0 | 11(10.1%) | 14.0(9) | |
| 1 | 34(31.2%) | 15.5(9) | |
| 2 | 49(45.0%) | 15.0(6) | |
| 3 | 15(13.8%) | 15.0(6) | |
| Tumor size | 0.049# | ||
| ≤ 2 cm | 50(45.9%) | 14.0(6) | |
| > 2 cm | 59(54.1%) | 17.0(7) | |
| Distal margin | 0.064# | ||
| ≤ 1.5 cm | 63(57.8%) | 15.0(7) | |
| > 1.5 cm | 46(42.2%) | 17.0(5) | |
| Surgery duration | 0.752# | ||
| ≤ 225 min | 55(50.5%) | 15.0(6) | |
| > 225 min | 54(49.5%) | 16.0(7) | |
| Blood loss | 0.337# | ||
| < 100 ml | 36(33.0%) | 15.5(5) | |
| ≥ 100 ml | 73(67.0%) | 15.0(7) | |
**Kruskal–Wallis test
# Mann–Whitney U test